BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2026)
BridgeBio Pharma (BBIO) reported Return on Capital Employed of 155.72% for Q1 2026, down 6250.0% on a YoY basis from 2.53% in Q1 2025, and down 102.06% sequentially from 77.07% in Q4 2025.
BridgeBio Pharma (BBIO) Return on Capital Employed (2019 - 2026) Analysis & Trends
BridgeBio Pharma (BBIO) has 8 years of Return on Capital Employed data on file, last reported at 155.72% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 6250.0% year-over-year to 155.72%; the trailing twelve-month figure through Mar 2026 stood at 155.72% (down 6250.0% YoY), and the FY2025 full-year result was 81.82%, up 2069.0% from the prior year.
- Return on Capital Employed fell to 155.72% in Q1 2026, from 77.07% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 72.0% in Q1 2022 to a low of 155.72% in Q1 2026.
- A 5-year average of 94.74% and a median of 88.05% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 4251 bps in 2024 and slumped 6250 bps in 2026, its largest moves.
- Tracing BBIO's Return on Capital Employed over 5 years: stood at 92.38% in 2022, then slumped by 44 bps to 132.95% in 2023, then soared by 30 bps to 92.98% in 2024, then gained by 17 bps to 77.07% in 2025, then plunged by 102 bps to 155.72% in 2026.
- Business Quant data shows BBIO's Return on Capital Employed at 155.72% in Q1 2026, 77.07% in Q4 2025, and 74.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | BridgeBio Pharma | 16.15 Bn | 15.22 Bn | 184.58 Mn | -155.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -155.72% |
| Dec 31, 2025 | -77.07% |
| Sep 30, 2025 | -74.14% |
| Jun 30, 2025 | -81.54% |
| Mar 31, 2025 | -93.23% |
| Dec 31, 2024 | -92.98% |
| Sep 30, 2024 | -92.19% |
| Jun 30, 2024 | -74.23% |
| Mar 31, 2024 | -86.43% |
| Dec 31, 2023 | -132.95% |
| Sep 30, 2023 | -118.15% |
| Jun 30, 2023 | -116.73% |
| Mar 31, 2023 | -88.05% |
| Dec 31, 2022 | -92.38% |
| Sep 30, 2022 | -81.12% |
| Jun 30, 2022 | -81.69% |
| Mar 31, 2022 | -72.00% |
| Dec 31, 2021 | -75.66% |
| Sep 30, 2021 | -64.44% |
| Jun 30, 2021 | -53.27% |